Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon10.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-PIK3R1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PI 3 Kinase p85 alpha also known as PI3KR1 or phospho PI3K is a regulatory subunit of phosphoinositide 3-kinase (PI3K) that plays a fundamental role in various signaling pathways. The p85 protein has a molecular weight of approximately 85 kDa. This protein is widely expressed in many cell types facilitating essential cellular functions by forming a heterodimer with the class I PI3K catalytic subunit often implicated in regulating lipid signaling pathways.
Biological function summary
P85 alpha modulates intracellular signaling by interacting with other proteins in a complex formation with catalytic subunit p110. This interaction enables the initiation of downstream signaling cascades controlling cell growth proliferation and survival. PI 3 kinase activity mediated by p85 alpha is integral to cellular homeostasis and metabolism helping to execute cellular responses to a variety of growth factors and hormones.
Pathways
PI 3 Kinase p85 alpha integrates into two principal signaling networks: the PI3K-Akt and mTOR pathways. These pathways are instrumental for regulating anabolic processes and cell survival. The p85 form of PI3K interacts with additional proteins such as Akt and mTOR coordinating cellular energy balance promoting protein synthesis and inhibiting apoptosis. Through these interactions the protein ensures that cells respond accurately to nutritional and stress signals.
Alterations in PI 3 Kinase p85 alpha function have been linked to cancer and type 2 diabetes. Aberrant signaling involving PI3K-Akt-mTOR pathways due to mutations in PI3KR1 can contribute to tumor progression and chemoresistance. Moreover dysfunction of this pathway affects insulin signaling connecting p85 alpha to diabetic pathologies. Proteins such as IRS-1 (insulin receptor substrate 1) act alongside p85 alpha in mediating these disease-associated processes emphasizing its importance in maintaining physiological balance.
